Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 319 Neoadjuvant Therapy in HNSCC
NCT02540928Phase 2Terminated
- Sponsor
- Cancer Research UK
- Start
- Oct 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AMG-319 in head and neck squamous cell carcinoma (HNSCC), sponsored by Cancer Research UK. Started Oct 2015; status: terminated.
02
Drugs
AMG-319
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02540928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02540928.